The Importance of De-escalating Antimicrobial Therapy in Patients with Ventilator-Associated Pneumonia

ABSTRACT

The management of ventilator-associated pneumonia (VAP) requires a strategy for antibiotic use that achieves prompt and accurate empirical therapy without overusing antibiotics. Although, efforts at better diagnosis and antibiotic restriction have been attempted, “de-escalation” may be a more useful and effective strategy, and one that can achieve these goals while improving patient outcomes. The centerpiece of this approach is to initiate empirical therapy with a broad-spectrum treatment regimen, based on knowledge of local patterns of microbiology and antimicrobial resistance. Prior to therapy, patients require collection of a lower respiratory tract sample for culture. After 2 to 3 days, the clinical course can be assessed and the culture data reviewed, and in responding patients, efforts can be made to change the initial broad-spectrum therapy. This de-escalation can involve focusing to a more narrow spectrum agent, reducing the number of antibiotics, stopping therapy altogether in patients not likely to have infection, and making efforts to reduce duration of therapy. When this strategy has been used, outcomes such as the frequency of secondary infection, antimicrobial resistance, and mortality have improved. Additional information is needed to apply this approach more widely, especially in patients infected with multidrug-resistant organisms and in those with negative lower respiratory tract cultures.

De-escalation - antimicrobial resistance - ventilator-associated pneumonia (VAP) therapy - therapeutic protocols

REFERENCES

• 1 Hoffken G, Niederman M S. Nosocomial pneumonia: the importance of a de-escalating strategy for antibiotic treatment of pneumonia in the ICU.  Chest. 2002;  122 2183-2196
• 2 Kollef M H, Sherman G, Ward S, Fraser V. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients.  Chest. 1999;  115 462-474
• 3 Luna C M, Vujacich P, Niederman M S et al.. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia.  Chest. 1997;  111 676-685
• 4 Niederman M S, Craven D E, Bonten M J et al.. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.  Am J Respir Crit Care Med. 2005;  171 388-416
• 5 Trouillet J L, Chastre J, Vuagnat A et al.. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria.  Am J Respir Crit Care Med. 1998;  157 531-539
• 6 Rello J, Sa-Borges M, Correa H, Leal S R, Baraibar J. Variations in etiology of ventilator-associated pneumonia across four treatment sites: implications for antimicrobial prescribing practices.  Am J Respir Crit Care Med. 1999;  160 608-613
• 7 Namias N, Samiian L, Nino D et al.. Incidence and susceptibility of pathogenic bacteria vary between intensive care units within a single hospital: implications for empiric antibiotic strategies.  J Trauma. 2000;  49 638-645
• 8 Ibrahim E H, Ward S, Sherman G, Schaiff R, Fraser V J, Kollef M H. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia.  Crit Care Med. 2001;  29 1109-1115
• 9 Micek S T, Ward S, Fraser V J, Kollef M H. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia.  Chest. 2004;  125 1791-1799
• 10 Souweine B, Veber B, Bedos J P et al.. Diagnostic accuracy of protected specimen brush and bronchoalveolar lavage in nosocomial pneumonia: impact of previous antimicrobial treatments.  Crit Care Med. 1998;  26 236-244
• 11 Dennesen P J, Van der Ven A J, Kessels A G, Ramsay G, Bonten M J. Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia.  Am J Respir Crit Care Med. 2001;  163 1371-1375
• 12 Luna C M, Blanzaco D, Niederman M S et al.. Resolution of ventilator-associated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome.  Crit Care Med. 2003;  31 676-682
• 13 Rello J, Vidaur L, Sandiumenge A et al.. De-escalation therapy in ventilator-associated pneumonia.  Crit Care Med. 2004;  32 2183-2190
• 14 Niederman M S. Therapy of ventilator-associated pneumonia: what more can we do to use less antibiotics?.  Crit Care Med. 2004;  32 2344-2345
• 15 Chastre J, Wolff M, Fagon J Y et al.. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial.  JAMA. 2003;  290 2588-2598
• 16 Paul M, Benuri-Silbiger I, Soares-Weiser K, Liebovici L. Beta-lactam monotherapy versus beta-lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials.  BMJ. 2004;  328 668
• 17 Bliziotis I A, Samonis G, Vardakas K Z, Chrysanthoupoulou S, Falagas M E. Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials.  Clin Infect Dis. 2005;  41 149-158
• 18 Fink M P, Snydman D R, Niederman M S et al.. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.  Antimicrob Agents Chemother. 1994;  38 547-557
• 19 Sieger B, Berman S J, Geckler R W, Farkas S A. Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study. Meropenem Lower Respiratory Infection Group.  Crit Care Med. 1997;  25 1663-1670
• 20 West M, Boulanger B R, Fogarty C et al.. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study.  Clin Ther. 2003;  25 485-506
• 21 Joshi M, Bernstein J, Solomkin J, Wester B A, Kuye O. Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin for the treatment of patients with nosocomial lower respiratory tract infection. Piperacillin/tazobactam Nosocomial Pneumonia Study Group.  J Antimicrob Chemother. 1999;  43 389-397
• 22 Gruson D, Hilbert G, Vargas F et al.. Strategy of antibiotic rotation: long-term effect on incidence and susceptibilities of gram-negative bacilli responsible for ventilator-associated pneumonia.  Crit Care Med. 2003;  31 1908-1914
• 23 Kollef M H, Niederman M S, Leeper K V et al.. Escalation/de-escalation of initial empiric ventilator-associated pneumonia therapy: interim results from the assessment of local antimicrobial resistance measures study.  Chest. 2004;  126 718 S
• 24 Singh N, Rogers P, Atwood C W, Wagener M M, Yu V L. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit: a proposed solution for indiscriminate antibiotic prescription.  Am J Respir Crit Care Med. 2000;  162 505-511
• 25 Hamer D H. Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin.  Am J Respir Crit Care Med. 2000;  162 328-330
• 26 Baughman R P, Kerr M A. Ventilator-associated pneumonia patients who do not reduce bacterial from the lungs have a worse prognosis.  J Intensive Care Med. 2003;  18 269-274